CG Oncology CFO granted options on 90,574 shares
CG Oncology, Inc. reported that Chief Financial Officer James M. Detore received an employee stock option grant covering 90,574 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CG Oncology, Inc. reported that Chief Financial Officer James M. Detore received an employee stock option grant covering 90,574 shares of common stock. The option has an exercise price of $67.68 per share and expires on April 14, 2036.
According to the vesting terms, the option vests over four years starting on April 15, 2026, with 25% of the shares vesting 12 months after that date and the remaining 75% vesting in 36 equal monthly installments over the following three years. This is a compensation-related award rather than an open-market purchase.
Insider Trade Summary
Grant/Award: 90,574 shares
Grant/Award
1 txn
Insider
DETORE JAMES M.
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 90,574 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 90,574 contracts (Direct)
Footnotes (1)
- F1. The stock option vests over a four-year period starting on April 15, 2026 (the "Vesting Commencement Date"), with 25% of the shares vesting on the date that is twelve months after the Vesting Commencement Date and the remainder vesting in thirty-six equal monthly installments over the subsequent three-year period.
Key Figures
Option grant size: 90,574 shares
Exercise price: $67.68 per share
Expiration date: April 14, 2036
+3 more
6 metrics
Option grant size
90,574 shares
Employee stock option award to CFO
Exercise price
$67.68 per share
Stock option strike price
Expiration date
April 14, 2036
Option term end date
Vesting commencement
April 15, 2026
Start of vesting schedule
Cliff vesting portion
25% of shares
Vests 12 months after commencement
Remainder vesting period
36 monthly installments
Remaining 75% over three years
Key Terms
Employee Stock Option, Vesting Commencement Date, derivative securities, underlying security
4 terms
Employee Stock Option financial
"security_title: "Employee Stock Option (Right to Buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Vesting Commencement Date financial
"starting on April 15, 2026 (the "Vesting Commencement Date")"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
derivative securities financial
"transaction_type: "derivative" for the option grant"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
underlying security financial
"underlying_security_title: "Common Stock""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CGON’s CFO report in this Form 4 filing?
CG Oncology’s CFO, James M. Detore, reported receiving an option grant for 90,574 shares of common stock. This is a compensation-related stock option award, not an open-market stock purchase or sale, and reflects part of his long-term incentive package.
What is the exercise price of the CGON CFO’s stock options?
The exercise price for the CFO’s stock options is $67.68 per share. This means he can purchase each underlying share at $67.68 once the options vest and are exercised, provided the options are still outstanding before their stated expiration date in 2036.
When do the CGON CFO’s options begin vesting and how is vesting structured?
The options begin vesting on April 15, 2026, the Vesting Commencement Date. Twenty-five percent of the shares vest 12 months afterward, and the remaining 75% vest in 36 equal monthly installments over the next three years, creating a four-year vesting period.
When do the CGON CFO’s stock options expire?
The CFO’s employee stock option grant expires on April 14, 2036. After that expiration date, any unexercised portion of the option can no longer be used to purchase CG Oncology common shares, even if vesting conditions had previously been satisfied.
Is this CGON Form 4 a stock purchase or sale by the CFO?
This Form 4 reflects a grant of employee stock options, not a stock purchase or sale. It is classified as an acquisition of derivative securities as compensation, with no open-market buying or selling of CG Oncology common stock reported in this particular filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
